Boston Scientific said its profits rose 12 percent in the fourth quarter despite declining sales. The company said overall sales were down 4 percent. Sales of the company's best known product, the Taxus drug-coated stent, fell 12 percent to $606 million from $691 million. More details are expected today on how Boston Scientific plans to handle the quality control problems raised recently by the FDA. Article [1]
Links:
[1] http://www.washingtonpost.com/wp-dyn/content/article/2006/02/07/AR2006020700456.html